Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB16778 | Lutetium Lu-177 vipivotide tetraxetan | A radioligand therapeutic agent used to treat prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer in adults. |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB16778 | Lutetium Lu-177 vipivotide tetraxetan | Prostate-specific antigen | target |
| Drug | Drug Name | Phase | Status | Count |
|---|